Cost-effectiveness of obinutuzumab versus rituximab biosimilars for previously untreated follicular lymphoma

BACKGROUND: In the randomized phase 3 GALLIUM trial, first-line treatment with obinutuzumab (GA101; G) plus chemotherapy (G + chemo) resulted in superior progression-free survival (PFS) compared with rituximab plus chemotherapy (R + chemo) for patients with follicular lymphoma (FL). G + chemo was fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Spencer, Scott J, Guzauskas, Gregory F, FeLizzi, Federico, Launonen, Aino, Dawson, Keith, Veenstra, David L, Masaquel, Anthony
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394221/
https://www.ncbi.nlm.nih.gov/pubmed/33586513
http://dx.doi.org/10.18553/jmcp.2021.20424

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394221/
https://www.ncbi.nlm.nih.gov/pubmed/33586513
http://dx.doi.org/10.18553/jmcp.2021.20424

Ejemplares similares